Allergy Shots Work — Here Is the Full Evidence Cascade

The Cochrane systematic review by Calderon et al. (2007) is the gold standard evidence for allergy shots in allergic rhinitis — synthesizing 51 double-blind randomized controlled trials in 2,871 patients across grass, ragweed, Parietaria, birch, and cedar allergens. Pooled symptom score SMD was -0.73 (a moderate-to-large effect) and medication score SMD was -0.57, both highly statistically significant. For asthma, the Abramson Cochrane review (2010, 88 RCTs, ~3,500 patients) found symptom SMD -0.59. The EAACI systematic review (Dhami 2017) replicated these results independently. Long-term follow-up by Durham (NEJM 1999) and Eng (Allergy 2006) confirmed disease-modifying effects persisting 3 to 12 years after stopping. Collectively, this is one of the most thoroughly evidenced treatments in respiratory medicine.

Allergy shots have been documented to work for over 100 years. Leonard Noon first reported subcutaneous grass pollen immunotherapy for hay fever in The Lancet in 1911. Since then, the evidence base has evolved from open-label case series to double-blind placebo-controlled RCTs to Cochrane meta-analyses. Modern double-blind RCTs have been the standard since at least the 1970s, with landmark studies from Lichtenstein, Norman, and Van Metre establishing the dose-response relationship and adequate-dosing requirements. The 2007 and 2010 Cochrane reviews synthesize this century-long accumulation of evidence. The consistent positive signal across 100-plus years, multiple allergens, and multiple countries is perhaps the most compelling argument of all.

Allergy shots produce durable long-term benefit rather than guaranteed permanent cure. Durham et al. (NEJM 1999) showed benefits maintained at least 3 years after stopping a 3- to 4-year grass SCIT course, and Eng et al. (Allergy 2006) confirmed benefit at 12-year post-treatment follow-up in a small cohort. Approximately 75% of patients who complete a full course maintain their improvement 3 years after stopping; about 25% experience relapse. The most durable effects include prevention of new allergen sensitizations and reduced asthma development in children — effects documented for 7 to 10 years post-treatment in PAT study follow-ups. Venom immunotherapy after 5 years allows most patients to discontinue with maintained protection.

Allergy shots work best for patients with moderate-to-severe allergic rhinitis confirmed by skin test or specific IgE testing, with sensitization to 5 or fewer clinically relevant allergens, age 5 to 50, commitment to completing a 3- to 5-year course with more than 90% appointment adherence, and concurrent environmental control measures. Monosensitized patients (single primary allergen) achieve higher rates of complete remission than polysensitized patients. Children achieve better disease modification and asthma prevention than adults. Patients who begin immunotherapy within 5 years of symptom onset show better disease modification than those with long-standing disease. These predictors should guide shared decision-making with your allergist before committing to treatment.

Yes — the Abramson Cochrane review of 88 randomized controlled trials confirmed that allergy shots significantly reduce allergic asthma symptoms (SMD -0.59), medication use, and bronchial hyperreactivity. The evidence is strongest for dust mite-driven asthma in well-controlled, monosensitized patients. The PAT study and its follow-ups demonstrated that allergy shots in allergic-rhinitis children reduce asthma development odds by 50 to 71% over the following decade — one of the most powerful preventive effects in all of pediatric medicine. Critical caveat: uncontrolled asthma (FEV1 below 70%) is a contraindication for allergy shots due to increased systemic reaction risk. Asthma must be well-controlled before initiating or continuing SCIT.

Allergy shots become cost-saving compared to long-term medication use after approximately 3 years of treatment. Hankin et al. (JACI 2013) found that immunotherapy-treated patients had 33% lower total allergy-related healthcare costs compared to matched controls, with savings emerging as early as 3 months post-initiation in the pediatric Medicaid analysis. German health economic modeling (Brüggenjürgen 2008) projected break-even at approximately 10 years with lifetime savings. Over a decade, the net savings compared to ongoing pharmacotherapy are estimated at $6,000 to $12,000 per patient. The economic case for allergy shots is strongest for patients who will complete the full course — the 50 to 70% who drop out early achieve a fraction of both the clinical and economic benefit.